Alpelisib plus fulvestrant in PIK3CA-Altered and PIK3CA-wild-type estrogen receptor–positive advanced breast cancer: A phase 1b clinical trial (JAMA Oncology, 2018)

(untitled) - Juric, D; Janku, F; Rodón, J; Burris, H; Mayer, I; Schuler, M; Seggewiss-Bernhardt, R; Gil-Martin, M; Middleton, M; Baselga, J; Bootle, D; Demanse, D; et al.